TriangleTafasitamab (NCT07225439)
Tafasitamab trial for Non Hodgkin Lymphoma (NCT07225439). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
B-cell lymphoma is treatable, often curable, until it comes back. Then engineered CAR T cells changed everything. But they are built from each patient's own cells, take weeks, and fail in nearly half of those who get them.
The idea: an immune cell you can take off the shelf, and two antibodies to aim it.
Natural killer cells from a healthy donor are grown and infused weekly for three weeks. Alongside them, rituximab and tafasitamab coat the lymphoma cells, each grabbing a different surface marker. Coated cells are exactly what natural killer cells are built to destroy.
This trial, in Cleveland with Paolo Caimi and George Deng, is the first test of the combination, asking what dose is safe. Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.